Profile data is unavailable for this security.
About the company
Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
- Revenue in SEK (TTM)20.71m
- Net income in SEK-83.30m
- Incorporated2014
- Employees23.00
- LocationSaniona ABSmedeland 26BGLOSTRUP 2600DenmarkDNK
- Websitehttps://saniona.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ultimovacs ASA | 0.00 | -174.90m | 291.95m | 25.00 | -- | 1.15 | -- | -- | -5.17 | -5.17 | 0.00 | 7.53 | 0.00 | -- | -- | 0.00 | -44.31 | -28.80 | -50.09 | -31.12 | -- | -- | -- | -- | -- | -- | 0.0136 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Ascelia Pharma AB | 0.00 | -88.76m | 311.58m | 13.00 | -- | 5.12 | -- | -- | -2.63 | -2.63 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -65.17 | -- | -78.39 | -- | -- | -- | -- | -- | -- | -- | 0.2302 | -- | -- | -- | 16.72 | -- | -- | -- |
| Bactiquant A/S | 18.56m | -19.76m | 345.55m | -- | -- | 15.90 | -- | 18.62 | -0.6358 | -0.6358 | 0.5971 | 0.6133 | 0.5055 | 3.67 | 2.83 | -- | -53.83 | -41.26 | -62.59 | -47.16 | -6.14 | 12.89 | -106.51 | -71.77 | 5.43 | -8.54 | 0.0431 | -- | -0.689 | -- | 7.62 | -- | -- | -- |
| Medivir AB | 7.73m | -96.52m | 348.49m | 10.00 | -- | 1.65 | -- | 45.06 | -1.46 | -1.46 | 0.1028 | 1.89 | 0.032 | -- | 1.56 | 773,300.00 | -40.00 | -28.91 | -47.20 | -34.77 | -888.81 | -467.42 | -1,248.18 | -675.96 | -- | -- | 0.0482 | -- | 73.16 | -20.39 | -0.6275 | -- | -47.96 | -- |
| INIFY Laboratories AB | 3.42m | -51.35m | 352.57m | 23.00 | -- | 4.83 | -- | 103.21 | -1.15 | -1.15 | 0.0768 | 1.64 | 0.032 | 2.99 | 0.6608 | -- | -48.10 | -- | -48.10 | -- | 76.42 | -- | -1,503.10 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- |
| Magle Chemoswed Holding AB | 170.01m | 12.23m | 360.72m | 78.00 | 29.50 | 2.23 | 14.40 | 2.12 | 1.13 | 1.13 | 15.74 | 14.95 | 0.6068 | 0.493 | 8.30 | 2,179,628.00 | 4.36 | 2.52 | 5.86 | 3.52 | 90.58 | 85.67 | 7.19 | 3.92 | 0.6356 | 6.35 | 0.3081 | -- | 17.00 | 9.97 | 33.07 | -- | -6.34 | -- |
| Herantis Pharma Oyj | 0.00 | 3.15m | 376.54m | 10.00 | 132.06 | 7.08 | 119.59 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| Lytix Biopharma AS | 3.92m | -86.42m | 386.33m | 10.00 | -- | 6.28 | -- | 98.45 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| Saniona AB | 20.71m | -83.30m | 432.72m | 23.00 | -- | 15.87 | -- | 20.89 | -1.09 | -1.09 | 0.2629 | 0.2451 | 0.1726 | -- | 5.63 | 900,521.80 | -69.41 | -59.16 | -127.89 | -70.15 | -136.88 | -970.05 | -402.20 | -1,483.55 | -- | -3.85 | 0.71 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| Xbrane Biopharma AB | 190.97m | -361.27m | 441.26m | 75.00 | -- | 1.12 | -- | 2.31 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Bergenbio ASA | 512.28k | -151.93m | 444.82m | 16.00 | -- | 333.46 | -- | 868.32 | -0.1849 | -0.1849 | 0.0003 | 0.0347 | 0.0047 | -- | 0.0485 | 20,840.00 | -139.81 | -66.15 | -275.19 | -78.74 | -- | -- | -29,658.54 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Enzymatica AB (publ) | 47.29m | -53.67m | 471.60m | 18.00 | -- | 5.62 | -- | 9.97 | -0.3247 | -0.3247 | 0.2866 | 0.4841 | 0.3269 | 1.38 | 6.48 | -- | -37.11 | -27.36 | -39.16 | -33.98 | 64.25 | 65.08 | -113.50 | -66.12 | -- | -23.26 | 0.2502 | -- | 4.00 | -0.6382 | 27.57 | -- | 7.02 | -- |
| Mendus AB (publ) | 0.00 | -107.07m | 472.37m | 28.00 | -- | 0.6023 | -- | -- | -3.15 | -3.15 | 0.00 | 15.57 | 0.00 | -- | -- | 0.00 | -16.09 | -18.84 | -17.35 | -20.21 | -- | -- | -- | -28,474.53 | -- | -- | 0.0348 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Lifecare ASA | 12.87m | -34.67m | 472.83m | 32.00 | -- | 5.96 | -- | 36.75 | -0.2454 | -0.2454 | 0.092 | 0.4163 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Hamlet BioPharma AB | 0.00 | -33.41m | 521.28m | 7.00 | -- | 9.01 | -- | -- | -0.2326 | -0.2326 | 0.00 | 0.453 | 0.00 | -- | -- | -- | -63.45 | -83.52 | -69.09 | -107.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Initiator Pharma A/S | 0.00 | -33.98m | 539.64m | 3.00 | -- | 16.01 | -- | -- | -0.6241 | -0.6241 | 0.00 | 0.6369 | 0.00 | -- | -- | 0.00 | -70.60 | -68.27 | -73.77 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
Data as of Jun 14 2024. Currency figures normalised to Saniona AB's reporting currency: Swedish Krona SEK
3.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tredje AP-fondenas of 29 Aug 2023 | 2.23m | 2.01% |
| Handelsbanken Fonder ABas of 31 May 2024 | 683.73k | 0.62% |
| SEB Investment Management ABas of 30 Apr 2024 | 419.02k | 0.38% |
| FCG Fonder ABas of 31 Dec 2023 | 187.71k | 0.17% |
| Skandia Investment Management ABas of 28 Mar 2024 | 29.63k | 0.03% |
| Storebrand Asset Management ASas of 31 Jan 2024 | 27.33k | 0.03% |
| Case Kapitalf�rvaltning ABas of 30 Nov 2022 | 18.70k | 0.02% |
| Abante Asesores Gesti�n SGIIC SAas of 30 Jun 2023 | 0.00 | 0.00% |
More ▼
Data from 31 Dec 2022 - 31 Mar 2024Source: FactSet Research Systems Inc.
